Reuters logo
BRIEF-Rexahn Pharmaceuticals posts Q3 loss per share $0.04
2017年11月6日 / 下午4点28分 / 12 天前

BRIEF-Rexahn Pharmaceuticals posts Q3 loss per share $0.04

Nov 6 (Reuters) - Rexahn Pharmaceuticals Inc

* Rexahn Pharmaceuticals reports third quarter 2017 financial results and provides corporate update

* Q3 loss per share $0.04

* Q3 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S

* Rexahn Pharmaceuticals Inc - Co received a positive opinion from european medicines agency on orphan drug designation for RX-3117 in pancreatic cancer​

* Rexahn Pharmaceuticals Inc- ‍Cash and investments totaled about $23.2 million as of Sept 30, 2017, compared to about $20.3 million as of Dec 31, 2016​

* Rexahn Pharmaceuticals Inc - ‍Expects that cash and investments will be sufficient to fund cash flow requirements for current activities into 2019​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below